CN118045160A - Composition for improving efficacy of coenzyme Q10 and application thereof - Google Patents
Composition for improving efficacy of coenzyme Q10 and application thereof Download PDFInfo
- Publication number
- CN118045160A CN118045160A CN202410196176.2A CN202410196176A CN118045160A CN 118045160 A CN118045160 A CN 118045160A CN 202410196176 A CN202410196176 A CN 202410196176A CN 118045160 A CN118045160 A CN 118045160A
- Authority
- CN
- China
- Prior art keywords
- coenzyme
- chitosan
- microsphere
- vitamin
- short peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000017471 coenzyme Q10 Nutrition 0.000 title claims abstract description 100
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 title claims abstract description 100
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 title claims abstract description 97
- 229940110767 coenzyme Q10 Drugs 0.000 title claims abstract description 95
- 239000000203 mixture Substances 0.000 title claims abstract description 74
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 102
- 229920001661 Chitosan Polymers 0.000 claims abstract description 80
- 239000004005 microsphere Substances 0.000 claims abstract description 63
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 57
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 51
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 51
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 51
- 229940046009 vitamin E Drugs 0.000 claims abstract description 51
- 239000011709 vitamin E Substances 0.000 claims abstract description 51
- 238000002360 preparation method Methods 0.000 claims abstract description 30
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 88
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 44
- 229960000583 acetic acid Drugs 0.000 claims description 33
- 238000004132 cross linking Methods 0.000 claims description 33
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 22
- 238000002156 mixing Methods 0.000 claims description 22
- 239000003208 petroleum Substances 0.000 claims description 22
- 206010003246 arthritis Diseases 0.000 claims description 13
- 239000005662 Paraffin oil Substances 0.000 claims description 11
- 238000004140 cleaning Methods 0.000 claims description 11
- 239000000839 emulsion Substances 0.000 claims description 11
- 238000004108 freeze drying Methods 0.000 claims description 11
- 239000012362 glacial acetic acid Substances 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 11
- AYEKOFBPNLCAJY-UHFFFAOYSA-O thiamine pyrophosphate Chemical compound CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N AYEKOFBPNLCAJY-UHFFFAOYSA-O 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 9
- 102000015636 Oligopeptides Human genes 0.000 claims description 7
- 108010038807 Oligopeptides Proteins 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000006378 damage Effects 0.000 abstract description 12
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 10
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract description 10
- 102000004889 Interleukin-6 Human genes 0.000 abstract description 9
- 108090001005 Interleukin-6 Proteins 0.000 abstract description 9
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 7
- 230000002757 inflammatory effect Effects 0.000 abstract description 6
- 208000027418 Wounds and injury Diseases 0.000 abstract description 5
- 210000000845 cartilage Anatomy 0.000 abstract description 5
- 208000014674 injury Diseases 0.000 abstract description 5
- 230000028327 secretion Effects 0.000 abstract description 5
- 210000000629 knee joint Anatomy 0.000 abstract description 4
- 230000017423 tissue regeneration Effects 0.000 abstract description 4
- 238000012795 verification Methods 0.000 abstract description 3
- 102000013691 Interleukin-17 Human genes 0.000 description 9
- 108050003558 Interleukin-17 Proteins 0.000 description 9
- 241000700159 Rattus Species 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940035936 ubiquinone Drugs 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010051728 Bone erosion Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000005189 cardiac health Effects 0.000 description 1
- 208000015606 cardiovascular system disease Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000005986 heart dysfunction Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 230000005499 meniscus Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N para-benzoquinone Natural products O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- -1 quinone compound Chemical class 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides a composition for improving the efficacy of coenzyme Q10 and application thereof. The composition is a slow release microsphere constructed by utilizing chitosan microsphere comprising coenzyme Q10, vitamin E and active short peptide, the microsphere preparation process flow is simpler, more convenient and efficient, the slow release effect is excellent, the release rate of the coenzyme Q10 in a patient can be effectively controlled, and the more efficient treatment effect is achieved. Proved by verification, the coenzyme Q10 composition can effectively inhibit secretion of IL-6, I L-17 and TNF-alpha, lighten inflammatory injury of knee joints and improve and promote damage of cartilage tissue repair.
Description
Technical Field
The invention relates to the technical field of arthritis treatment, in particular to a composition for improving the efficacy of coenzyme Q10 and application thereof.
Background
Ubiquinone (Ubiquinone, UQ), also known as Coenzyme Q (Coenzyme Q), is a lipid-soluble quinone compound that exists in nature. Coenzyme Q10 (Coenzyme Q, coQ 10) has the functions of improving human immunity, enhancing antioxidation, delaying aging, enhancing human activity and the like, is the most effective antioxidation component for preventing arteriosclerosis from forming, is widely used for cardiovascular system diseases in medicine, can prevent and control myocardial infarction, thrombus formation, heart failure, angina pectoris, heart beat abnormality and the like, can simultaneously reduce blood pressure, reduce blood fat, assist treatment and recovery after heart disease surgery, help athletes to avoid heart malfunction caused by excessive myocardial burden, effectively improve myocardial weakness, heart dysfunction and the like, and is widely used as a natural antioxidant and free radical scavenger for medical health products, cosmetic cosmetics and food additives at home and abroad. Is being pushed to be the most effective heart health care product in Europe and America and Japan.
Rheumatoid arthritis (rheumatoid arthritis, RA) is an autoimmune disease that is mainly clinically manifested by destruction of surrounding joints, cartilage and bones, and high expression of pro-inflammatory cytokines is a major cause of its pathogenesis. When human tissues are subjected to various harmful stimuli, free radicals generated in the tissues or cells are seriously unbalanced with the oxidation resistance of the organism, active oxygen is accumulated in the organism or the cells of the tissues, and a series of cellular inflammatory reactions can be caused, so that RA is generated and developed. Overexpression of tumor necrosis factor alpha (tumor necrosis factor α, TNF- α) can lead to synovitis, destruction of articular cartilage, and triggering expression of other inflammatory factors to further exacerbate the inflammatory response. Interleukin (interleukin, IL) -17 secreted by helper T cells (THELPER CELL, th) 17 acts as a pro-inflammatory cytokine, and its elevated levels during the acute phase of RA often suggest that the patient is ill and bone erosion is significant, mainly due to the fact that IL-17 stimulates different cell types to secrete various cytokines and chemokines in T-cell driven inflammation, destroying the bone repair system and causing bone destruction, joint deformity. Malondialdehyde is one of the end products of lipid oxidative damage, which increases in blood and synovial fluid of RA patients, and is associated with the severity of the disease.
However, the therapeutic effect of the currently clinically used coenzyme Q10 drugs on arthritis is to be improved.
Disclosure of Invention
Aiming at the technical problems existing in the prior art, the invention provides a composition for improving the drug effect of coenzyme Q10 and application thereof. The composition is a slow release microsphere constructed by utilizing chitosan microsphere comprising coenzyme Q10, vitamin E and short peptide. Proved by verification, the coenzyme Q10 composition can effectively inhibit secretion of IL-6, IL-17 and TNF-alpha, lighten inflammatory injury of knee joints and improve and promote damage of cartilage tissue repair.
Specifically, the invention firstly provides a composition for improving the drug effect of coenzyme Q10, which comprises 20-60mg of coenzyme Q10, 10-30 mug of active short peptide, 1-5mg of vitamin E and 200-500mg of chitosan. The composition is a slow release microsphere constructed by utilizing chitosan microsphere comprising coenzyme Q10, vitamin E and short peptide.
Preferably, the composition for improving the efficacy of coenzyme Q10 comprises 20mg of coenzyme Q10, 10 μg of active short peptide, 1mg of vitamin E and 200mg of chitosan. The composition is a slow release microsphere constructed by utilizing chitosan microsphere comprising coenzyme Q10, vitamin E and short peptide.
Preferably, the composition for improving the efficacy of coenzyme Q10 comprises 40mg of coenzyme Q10, 20 μg of active short peptide, 3mg of vitamin E and 300mg of chitosan. The composition is a slow release microsphere constructed by utilizing chitosan microsphere comprising coenzyme Q10, vitamin E and short peptide.
Preferably, the composition for improving the efficacy of coenzyme Q10 comprises 60mg of coenzyme Q10, 30 μg of active short peptide, 5mg of vitamin E and 500mg of chitosan. The composition is a slow release microsphere constructed by utilizing chitosan microsphere comprising coenzyme Q10, vitamin E and short peptide.
Preferably, the active short peptide selects the amino acid sequence of any one of SEQ ID NO. 1-3.
The invention also provides a preparation method of the composition for improving the drug effect of coenzyme Q10, which comprises the following steps:
1) Preparing chitosan acetic acid solution: mixing 200-500mg chitosan with 200-400mL glacial acetic acid solution, and dissolving for standby;
2) Preparing a disperse phase: dissolving 20-60mg of coenzyme Q10, 10-30 mug of active short peptide and 1-5mg of vitamin E in the chitosan acetic acid solution in the step 1) for standby;
3) Continuous phase preparation: taking a mixture of paraffin oil and petroleum ether according to a volume ratio of 1:1 as a continuous phase for standby;
4) Emulsion crosslinking: slowly adding the disperse phase in the step 2) into the continuous phase in the step 3), mechanically stirring for 1-2h, dropwise adding 5-15% (W/V) of TPP solution after completely and uniformly mixing, and fully crosslinking for 1-2h;
5) Microsphere preparation: and after the crosslinking is finished, repeatedly cleaning the chitosan microsphere with the embedded coenzyme Q10, vitamin E and active short peptide sequentially by using petroleum ether and isopropanol, and freeze-drying the chitosan microsphere for later use.
Preferably, the active short peptide selects the amino acid sequence of any one of SEQ ID NO. 1-3.
Further preferably, the method for preparing the composition for improving the efficacy of coenzyme Q10 comprises the following steps:
1) Preparing chitosan acetic acid solution: mixing 200mg of chitosan with 200mL of glacial acetic acid solution for dissolving for standby;
2) Preparing a disperse phase: dissolving 20mg of coenzyme Q10, 10 mug of active short peptide and 1mg of vitamin E in the chitosan acetic acid solution in the step 1) for standby;
3) Continuous phase preparation: taking a mixture of paraffin oil and petroleum ether according to a volume ratio of 1:1 as a continuous phase for standby;
4) Emulsion crosslinking: slowly adding the disperse phase in the step 2) into the continuous phase in the step 3), mechanically stirring for 1h, dropwise adding 5% (W/V) of TPP solution after completely and uniformly mixing, and fully crosslinking for 1h;
5) Microsphere preparation: and after the crosslinking is finished, repeatedly cleaning the chitosan microsphere with the embedded coenzyme Q10, vitamin E and active short peptide sequentially by using petroleum ether and isopropanol, and freeze-drying the chitosan microsphere for later use.
Wherein, the active short peptide selects SEQ ID NO.1.
Further preferably, the method for preparing the composition for improving the efficacy of coenzyme Q10 comprises the following steps:
1) Preparing chitosan acetic acid solution: mixing 300mg of chitosan with 300mL of glacial acetic acid solution, and dissolving for later use;
2) Preparing a disperse phase: 40mg of coenzyme Q10, 20 mug of active short peptide and 3mg of vitamin E are taken and dissolved in the chitosan acetic acid solution in the step 1) for standby;
3) Continuous phase preparation: taking a mixture of paraffin oil and petroleum ether according to a volume ratio of 1:1 as a continuous phase for standby;
4) Emulsion crosslinking: slowly adding the disperse phase in the step 2) into the continuous phase in the step 3), mechanically stirring for 1.5h, dropwise adding 10% (W/V) of TPP solution after completely and uniformly mixing, and fully crosslinking for 1.5h;
5) Microsphere preparation: and after the crosslinking is finished, repeatedly cleaning the chitosan microsphere with the embedded coenzyme Q10, vitamin E and active short peptide sequentially by using petroleum ether and isopropanol, and freeze-drying the chitosan microsphere for later use.
Wherein, the active short peptide selects SEQ ID NO.2.
Further preferably, the method for preparing the composition for improving the efficacy of coenzyme Q10 comprises the following steps:
1) Preparing chitosan acetic acid solution: mixing 500mg of chitosan with 400mL of glacial acetic acid solution for dissolving for standby;
2) Preparing a disperse phase: 60mg of coenzyme Q10, 30 mug of active short peptide and 5mg of vitamin E are taken and dissolved in the chitosan acetic acid solution in the step 1) for standby;
3) Continuous phase preparation: taking a mixture of paraffin oil and petroleum ether according to a volume ratio of 1:1 as a continuous phase for standby;
4) Emulsion crosslinking: slowly adding the disperse phase in the step 2) into the continuous phase in the step 3), mechanically stirring for 2h, dropwise adding 15% (W/V) of TPP solution after completely and uniformly mixing, and fully crosslinking for 2h;
5) Microsphere preparation: and after the crosslinking is finished, repeatedly cleaning the chitosan microsphere with the embedded coenzyme Q10, vitamin E and active short peptide sequentially by using petroleum ether and isopropanol, and freeze-drying the chitosan microsphere for later use.
Wherein, the active short peptide selects SEQ ID NO.3.
The invention also aims to provide the application of the composition in preparing medicines for treating arthritis.
The invention has the following advantages: the invention provides a composition for improving the drug effect of coenzyme Q10 for the first time, which is a slow release microsphere constructed by chitosan microsphere comprising coenzyme Q10, vitamin E and short peptide, the microsphere preparation process flow is simpler and more efficient, the slow release effect is excellent, the release rate of coenzyme Q10 in a patient can be effectively controlled, and the more efficient therapeutic effect is achieved. Proved by verification, the coenzyme Q10 composition can effectively inhibit secretion of IL-6, IL-17 and TNF-alpha, lighten inflammatory injury of knee joints and improve and promote damage of cartilage tissue repair.
Detailed Description
The present invention will be described in further detail with reference to specific examples so as to more clearly understand the present invention by those skilled in the art.
Example 1
A composition for improving the efficacy of coenzyme Q10, comprising 20mg of coenzyme Q10, 10 μg of active oligopeptide, 1mg of vitamin E, 200mg of chitosan. The composition is a slow release microsphere constructed by utilizing chitosan microsphere comprising coenzyme Q10, vitamin E and short peptide.
Wherein, the active short peptide selects SEQ ID NO.1.
Further, the preparation method of the coenzyme Q10 composition for preventing and treating arthritis comprises the following steps:
6) Preparing chitosan acetic acid solution: mixing 200mg of chitosan with 200mL of glacial acetic acid solution for dissolving for standby;
7) Preparing a disperse phase: dissolving 20mg of coenzyme Q10, 10 mug of active short peptide and 1mg of vitamin E in the chitosan acetic acid solution in the step 1) for standby;
8) Continuous phase preparation: taking a mixture of paraffin oil and petroleum ether according to a volume ratio of 1:1 as a continuous phase for standby;
9) Emulsion crosslinking: slowly adding the disperse phase in the step 2) into the continuous phase in the step 3), mechanically stirring for 1h, dropwise adding 5% (W/V) of TPP solution after completely and uniformly mixing, and fully crosslinking for 1h;
10 Microsphere preparation: and after the crosslinking is finished, repeatedly cleaning the chitosan microsphere with the embedded coenzyme Q10, vitamin E and active short peptide sequentially by using petroleum ether and isopropanol, and freeze-drying the chitosan microsphere for later use.
Example 2
A composition for improving the efficacy of coenzyme Q10, comprising 40mg of coenzyme Q10, 20 μg of active oligopeptide, 3mg of vitamin E, 300mg of chitosan. The composition is a slow release microsphere constructed by utilizing chitosan microsphere comprising coenzyme Q10, vitamin E and short peptide.
Wherein, the active short peptide selects SEQ ID NO.2.
Further, the preparation method of the coenzyme Q10 composition for preventing and treating arthritis comprises the following steps:
6) Preparing chitosan acetic acid solution: mixing 300mg of chitosan with 300mL of glacial acetic acid solution, and dissolving for later use;
7) Preparing a disperse phase: 40mg of coenzyme Q10, 20 mug of active short peptide and 3mg of vitamin E are taken and dissolved in the chitosan acetic acid solution in the step 1) for standby;
8) Continuous phase preparation: taking a mixture of paraffin oil and petroleum ether according to a volume ratio of 1:1 as a continuous phase for standby;
9) Emulsion crosslinking: slowly adding the disperse phase in the step 2) into the continuous phase in the step 3), mechanically stirring for 1.5h, dropwise adding 10% (W/V) of TPP solution after completely and uniformly mixing, and fully crosslinking for 1.5h;
10 Microsphere preparation: and after the crosslinking is finished, repeatedly cleaning the chitosan microsphere with the embedded coenzyme Q10, vitamin E and active short peptide sequentially by using petroleum ether and isopropanol, and freeze-drying the chitosan microsphere for later use.
Example 3
A composition for improving the efficacy of coenzyme Q10, comprising 60mg of coenzyme Q10, 30 μg of active oligopeptide, 5mg of vitamin E, 500mg of chitosan. The composition is a slow release microsphere constructed by utilizing chitosan microsphere comprising coenzyme Q10, vitamin E and short peptide.
Wherein, the active short peptide selects SEQ ID NO.3.
Further, the preparation method of the coenzyme Q10 composition for preventing and treating arthritis comprises the following steps:
11 Chitosan acetic acid solution preparation: mixing 500mg of chitosan with 400mL of glacial acetic acid solution for dissolving for standby;
12 Preparation of a dispersed phase: 60mg of coenzyme Q10, 30 mug of active short peptide and 5mg of vitamin E are taken and dissolved in the chitosan acetic acid solution in the step 1) for standby;
13 Continuous phase preparation: taking a mixture of paraffin oil and petroleum ether according to a volume ratio of 1:1 as a continuous phase for standby;
14 Emulsion crosslinking): slowly adding the disperse phase in the step 2) into the continuous phase in the step 3), mechanically stirring for 2h, dropwise adding 15% (W/V) of TPP solution after completely and uniformly mixing, and fully crosslinking for 2h;
15 Microsphere preparation: and after the crosslinking is finished, repeatedly cleaning the chitosan microsphere with the embedded coenzyme Q10, vitamin E and active short peptide sequentially by using petroleum ether and isopropanol, and freeze-drying the chitosan microsphere for later use.
Comparative example 1
A coenzyme Q10 composition was prepared in the same manner as in example 1 except that the composition did not contain an active oligopeptide.
Comparative example 2
A coenzyme Q10 composition was prepared in the same manner as in example 1 except that vitamin E was not contained in the composition.
Comparative example 3
A coenzyme Q10 composition was prepared by the same procedure as in example 1, except that only coenzyme Q10 was present in the composition.
Test example 1
In order to evaluate the sustained release efficacy of the coenzyme Q10 composition for preventing and treating arthritis prepared according to the present invention. 15mg of the coenzyme Q10 composition prepared in the invention obtained in examples 1-3 was dissolved in 20mL of PBS solution, placed in a shaking table at a constant temperature of 37℃and shaken at a constant speed of 200r/min, sampled at intervals, and analyzed by liquid chromatography for the release amounts of coenzyme Q10, active short peptide and vitamin E in the samples. The results show that:
At day 1, the release rates of coenzyme Q10 reached 8.25%, 15.12% and 20.35%, respectively, followed by release at a relatively slow rate, sustained release until day 15, the coenzyme Q10 compositions of examples 1-3 reached 96.25.+ -. 0.23%, 97.36.+ -. 0.52% and 98.25.+ -. 0.05%, respectively;
At day 1, the release rates of the active short peptides reached 5.25%, 10.33% and 12.45%, respectively, followed by release at a relatively slow rate, and sustained release until day 15, the coenzyme Q10 compositions of examples 1-3 reached 86.56.+ -. 0.52%, 91.50.+ -. 0.32% and 92.45.+ -. 0.45%, respectively;
vitamin E release rates reached 7.56%, 14.38% and 17.85%, respectively, at day 1, followed by release at a relatively slow rate, and sustained release until day 15, the coenzyme Q10 compositions of examples 1-3 reached 90.12.+ -. 0.43%, 92.78.+ -. 0.56% and 94.63.+ -. 0.28%, respectively;
the above results show that: the coenzyme Q10 composition prepared by the invention has good slow release effect, can release active ingredients for a long time with high efficiency, and effectively improves the treatment effect of coenzyme Q10.
Test example 2
Taking example 1 as an example, the effect of the medicament of the invention in preventing and treating arthritis is further demonstrated. Specifically, a plurality of SD rats with a weight of about 300g are selected, an inner meniscus unstable operation is adopted to construct a rat osteoarthritis model, rats with successful modeling are selected and evenly divided into a blank group, a control group 1-3 and a treatment group 1-3, wherein the blank group is not treated by any drug during the monitoring period, the control group 1-3 is sequentially administered with 0.2mg/kg of the composition described in the comparative example 1-3 every day, the treatment group 1-3 is sequentially administered with 0.2mg/kg of the composition described in the example 1-3 every day, and the administration is continued for one week. After the end of the administration, serum from the rat sample was collected and analyzed for secretion of IL-6, IL-17 and TNF-alpha by ELISA kit.
The results are shown in Table 1: the levels of IL-6, IL-17 and TNF-alpha in serum from rats in the osteoarthritis model were significantly higher in general, whereas the levels of IL-6, IL-17 and TNF-alpha in serum from rats in the control model were slightly reduced compared to the blank, but not significantly (p > 0.05). Whereas the therapeutic effect of examples 1-3 of the present invention showed: IL-6, IL-17 and TNF-alpha in serum showed a dramatic decrease, with a very significant difference (p < 0.05) compared to the control group. Particularly, under the combined use of coenzyme Q10, active short peptide and vitamin E, the coenzyme Q10 composition for preventing and treating arthritis can inhibit secretion of IL-6, IL-17 and TNF-alpha, lighten inflammatory injury of knee joint and improve and promote damage of cartilage tissue repair.
TABLE 1 analysis of the protective effect of coenzyme Q10 compositions on inflammatory injury to the knee
| Group of | IL-6(pg/ml) | IL-17(pg/ml) | TNF-ɑ(pg/ml) |
| Blank group | 0.25±0.52 | 35.25±6.22 | 6.63±0.98 |
| Control group 1 | 0.20±0.40 | 30.34±1.45 | 6.07±0.15 |
| Control group 2 | 0.22±0.05 | 32.35±2.06 | 6.21±0.25 |
| Control group 3 | 0.24±0.05 | 34.35±1.35 | 6.34±0.28 |
| Treatment group 1 | 0.12±0.12 | 11.36±0.89 | 2.68±0.42 |
| Treatment group 2 | 0.11±0.04 | 11.02±1.20 | 2.45±0.25 |
| Treatment group 3 | 0.10±0.23 | 10.35±2.36 | 2.25±0.12 |
It should be noted that the above examples are only for further illustrating and describing the technical solution of the present invention, and are not intended to limit the technical solution of the present invention, and the method of the present invention is only a preferred embodiment and is not intended to limit the scope of the present invention. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (10)
1.A composition for improving the efficacy of coenzyme Q10, which is characterized by comprising 20-60mg of coenzyme Q10, 10-30 μg of active short peptide, 1-5mg of vitamin E and 200-500mg of chitosan; the composition is a slow release microsphere constructed by utilizing chitosan microsphere comprising coenzyme Q10, vitamin E and short peptide.
2. The composition of claim 1, wherein the arthritis-controlling coenzyme Q10 composition comprises 20mg coenzyme Q10, 10 μg of active oligopeptide, 1mg vitamin E, 200mg chitosan; the composition is a slow release microsphere constructed by utilizing chitosan microsphere comprising coenzyme Q10, vitamin E and short peptide.
3. The composition of claim 1, wherein the arthritis-controlling coenzyme Q10 composition comprises 40mg coenzyme Q10, 20 μg of active oligopeptide, 3mg vitamin E, 300mg chitosan; the composition is a slow release microsphere constructed by utilizing chitosan microsphere comprising coenzyme Q10, vitamin E and short peptide.
4. The composition of claim 1, wherein the arthritis-controlling coenzyme Q10 composition comprises 60mg coenzyme Q10, 30 μg active oligopeptide, 5mg vitamin E, 500mg chitosan; the composition is a slow release microsphere constructed by utilizing chitosan microsphere comprising coenzyme Q10, vitamin E and short peptide.
5. The composition of any one of claims 1-4, wherein the active short peptide is selected from the amino acid sequences of any one of SEQ ID nos. 1-3.
6. A method for preparing a composition for improving the efficacy of coenzyme Q10, comprising the steps of:
1) Preparing chitosan acetic acid solution: mixing 200-500mg chitosan with 200-400mL glacial acetic acid solution, and dissolving for standby;
2) Preparing a disperse phase: dissolving 20-60mg of coenzyme Q10, 10-30 mug of active short peptide and 1-5mg of vitamin E in the chitosan acetic acid solution in the step 1) for standby;
3) Continuous phase preparation: taking a mixture of paraffin oil and petroleum ether according to a volume ratio of 1:1 as a continuous phase for standby;
4) Emulsion crosslinking: slowly adding the disperse phase in the step 2) into the continuous phase in the step 3), mechanically stirring for 1-2h, dropwise adding 5-15% (W/V) of TPP solution after completely and uniformly mixing, and fully crosslinking for 1-2h;
5) Microsphere preparation: after the crosslinking is finished, repeatedly cleaning the chitosan microsphere with the embedded coenzyme Q10, vitamin E and active short peptide sequentially by using petroleum ether and isopropanol, and freeze-drying the chitosan microsphere for later use;
Wherein the active short peptide selects the amino acid sequence of any one of SEQ ID NO. 1-3.
7. The method according to claim 6, characterized in that it comprises in particular the following steps:
1) Preparing chitosan acetic acid solution: mixing 200mg of chitosan with 200mL of glacial acetic acid solution for dissolving for standby;
2) Preparing a disperse phase: dissolving 20mg of coenzyme Q10, 10 mug of active short peptide and 1mg of vitamin E in the chitosan acetic acid solution in the step 1) for standby;
3) Continuous phase preparation: taking a mixture of paraffin oil and petroleum ether according to a volume ratio of 1:1 as a continuous phase for standby;
4) Emulsion crosslinking: slowly adding the disperse phase in the step 2) into the continuous phase in the step 3), mechanically stirring for 1h, dropwise adding 5% (W/V) of TPP solution after completely and uniformly mixing, and fully crosslinking for 1h;
5) Microsphere preparation: after the crosslinking is finished, repeatedly cleaning the chitosan microsphere with the embedded coenzyme Q10, vitamin E and active short peptide sequentially by using petroleum ether and isopropanol, and freeze-drying the chitosan microsphere for later use;
wherein, the active short peptide selects SEQ ID NO.1.
8. The method according to claim 6, characterized in that it comprises in particular the following steps:
1) Preparing chitosan acetic acid solution: mixing 300mg of chitosan with 300mL of glacial acetic acid solution, and dissolving for later use;
2) Preparing a disperse phase: 40mg of coenzyme Q10, 20 mug of active short peptide and 3mg of vitamin E are taken and dissolved in the chitosan acetic acid solution in the step 1) for standby;
3) Continuous phase preparation: taking a mixture of paraffin oil and petroleum ether according to a volume ratio of 1:1 as a continuous phase for standby;
4) Emulsion crosslinking: slowly adding the disperse phase in the step 2) into the continuous phase in the step 3), mechanically stirring for 1.5h, dropwise adding 10% (W/V) of TPP solution after completely and uniformly mixing, and fully crosslinking for 1.5h;
5) Microsphere preparation: after the crosslinking is finished, repeatedly cleaning the chitosan microsphere with the embedded coenzyme Q10, vitamin E and active short peptide sequentially by using petroleum ether and isopropanol, and freeze-drying the chitosan microsphere for later use;
Wherein, the active short peptide selects SEQ ID NO.2.
9. The method according to claim 6, characterized in that it comprises in particular the following steps:
1) Preparing chitosan acetic acid solution: mixing 500mg of chitosan with 400mL of glacial acetic acid solution for dissolving for standby;
2) Preparing a disperse phase: 60mg of coenzyme Q10, 30 mug of active short peptide and 5mg of vitamin E are taken and dissolved in the chitosan acetic acid solution in the step 1) for standby;
3) Continuous phase preparation: taking a mixture of paraffin oil and petroleum ether according to a volume ratio of 1:1 as a continuous phase for standby;
4) Emulsion crosslinking: slowly adding the disperse phase in the step 2) into the continuous phase in the step 3), mechanically stirring for 2h, dropwise adding 15% (W/V) of TPP solution after completely and uniformly mixing, and fully crosslinking for 2h;
5) Microsphere preparation: after the crosslinking is finished, repeatedly cleaning the chitosan microsphere with the embedded coenzyme Q10, vitamin E and active short peptide sequentially by using petroleum ether and isopropanol, and freeze-drying the chitosan microsphere for later use;
Wherein, the active short peptide selects SEQ ID NO.3.
10. Use of a composition according to any one of claims 1 to 5 in the manufacture of a medicament for the treatment of arthritis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410196176.2A CN118045160A (en) | 2024-02-22 | 2024-02-22 | Composition for improving efficacy of coenzyme Q10 and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410196176.2A CN118045160A (en) | 2024-02-22 | 2024-02-22 | Composition for improving efficacy of coenzyme Q10 and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118045160A true CN118045160A (en) | 2024-05-17 |
Family
ID=91051208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410196176.2A Pending CN118045160A (en) | 2024-02-22 | 2024-02-22 | Composition for improving efficacy of coenzyme Q10 and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118045160A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014118271A1 (en) * | 2013-01-31 | 2014-08-07 | Sochim International S.P.A. | Compositions for oral administration having a beneficial effect on cartilage disease, osteoarthritis and joint disease with an inflammatory component |
| CN115779000A (en) * | 2022-12-22 | 2023-03-14 | 广东润和生物科技有限公司 | Coenzyme Q10 composition for preventing and treating osteoarthritis |
| CN117180245A (en) * | 2023-10-26 | 2023-12-08 | 广东润和生物科技有限公司 | Coenzyme Q10 composition, preparation process thereof and application thereof in heart protection |
-
2024
- 2024-02-22 CN CN202410196176.2A patent/CN118045160A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014118271A1 (en) * | 2013-01-31 | 2014-08-07 | Sochim International S.P.A. | Compositions for oral administration having a beneficial effect on cartilage disease, osteoarthritis and joint disease with an inflammatory component |
| CN115779000A (en) * | 2022-12-22 | 2023-03-14 | 广东润和生物科技有限公司 | Coenzyme Q10 composition for preventing and treating osteoarthritis |
| CN117180245A (en) * | 2023-10-26 | 2023-12-08 | 广东润和生物科技有限公司 | Coenzyme Q10 composition, preparation process thereof and application thereof in heart protection |
Non-Patent Citations (1)
| Title |
|---|
| 朱科达;王凛介;刘风云;顾惠英;: "辅酶Q_(10)对类风湿关节炎患者促炎症细胞因子和氧化应激水平的影响", 广西医学, no. 04, 28 February 2020 (2020-02-28), pages 43 - 46 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69933763T2 (en) | BIODEGRADABLE ALGINATOR WITH DELAYED RELEASE | |
| JP5907886B2 (en) | Combination preparation with exosome and corticosteroid | |
| KR100345752B1 (en) | Pharmacolocial effect and extracting method for chronic osteoporosis and degenerative bone marrow diseases and rhematoid arthritis treatment by constituent drugs of oriental medicine | |
| US20160166516A1 (en) | Novel curcuminoid formulations and related methods of treatment | |
| KR101957014B1 (en) | Peptides having anti-inflammatory activity and composition the same for anti-inflammatory | |
| KR20180037058A (en) | Pharmaceutical compositions and uses thereof for reducing local fat | |
| JP2009531462A (en) | Combined use of polymer materials and other substances for improved performance | |
| CN1572318A (en) | Composition containing dipeptide of histidine and alanine for reducing uric acid | |
| Liang et al. | Xuezhikang improves the outcomes of cardiopulmonary resuscitation in rats by suppressing the inflammation response through TLR4/NF-κB pathway | |
| JP2008069143A (en) | Plant extract for treating rheumatoid arthritis | |
| KR101327150B1 (en) | Use of n-(2-aryl-propionyl)-sulfonamides for the treatment of spinal cord injury | |
| CN118045160A (en) | Composition for improving efficacy of coenzyme Q10 and application thereof | |
| CN117180245B (en) | Coenzyme Q10 composition, preparation process thereof and application thereof in heart protection | |
| CN112423752A (en) | Dosage and therapeutic efficacy of C5a antagonists and ANCA-associated vasculitis | |
| WO2004073700A1 (en) | Composition comprising cysteamine for improving immunity of animals | |
| US5908824A (en) | Nasally administrable compositions containing physiologically active peptides | |
| CA2459773A1 (en) | Enamel matrix protein compositions for modulating immune response | |
| KR20170012480A (en) | Cafestol for treating diabetes | |
| JP2024529777A (en) | Pharmaceutical compositions and applications of ARNi and calcium ion antagonists | |
| TWI435727B (en) | Use of modulating secretion of cytokines | |
| WO1998033474A1 (en) | Use of oil from emu or rhea birds as trans-membrane carriers for delivery of drugs, peptides and vaccines | |
| JP4439787B2 (en) | Oxytocin antagonist | |
| KR20130113581A (en) | Composition for preventing and treating atherosclerosis comprising hempseed extract | |
| EP3079709A1 (en) | Ephedra alata extracts and methods of use thereof | |
| US20230127213A1 (en) | A topical composition comprising an extract of combined herbs comprising longanae arillus for the treatment or alleviation of skin ulcer and the use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |